{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:14:11Z","timestamp":1794489251772,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100019018","name":"CAMS Initiative for Innovative Medicine","doi-asserted-by":"crossref","award":["2017-I2M-3-001"],"award-info":[{"award-number":["2017-I2M-3-001"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771757, 81671620, 81971545"],"award-info":[{"award-number":["81771757, 81671620, 81971545"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Capital Health Research and Development Special","award":["2020-2-4017"],"award-info":[{"award-number":["2020-2-4017"]}]},{"name":"National Key Research and Development Program of China","award":["No. 2016YFC0901500"],"award-info":[{"award-number":["No. 2016YFC0901500"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to investigate the role of serum IgE levels in the clinical features and outcomes of IgG4-related disease (IgG4-RD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively enrolled 459 newly diagnosed IgG4-RD patients with serum IgE examined at baseline from 2012 to 2019 and compared the clinical features between group A (serum IgE level\u2009\u2264\u200960 KU\/L) and group B (serum IgE level\u2009&gt;\u200960 KU\/L). Subsequently, 312 patients who had been followed up for \u2265\u20091\u2009year were further selected to evaluate the correlation between serum IgE level and disease outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, the serum IgE level was positively correlated with the serum IgG4 level (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.1779,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0001), eosinophil count (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.3004,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), and serum IgG level (\n                      <jats:italic>r<\/jats:italic>\n                      \u00a0=\u20090.2189,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) in IgG4-RD patients. Compared with group A, group B had more patients with allergic diseases (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.004), more organ involvement (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003), and higher IgG4-RD responder index scores (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002). During follow-up, group A patients had a higher remission induction rate than group B patients (88.4% vs. 73.6%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.035), while group B patients had a higher relapse rate than group A patients (29.0% vs. 16.2%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.039). Multivariate analysis found that a serum IgE level\u2009&gt;\u2009125 KU\/L at baseline was a risk factor for disease relapse (hazard ratio [HR], 1.894 [95% confidence interval (CI) 1.022\u20133.508];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.042). Cox regression analysis showed that elevation of the eosinophil count was a risk factor for relapse in both group A and group B patients (HR, 8.504 [95% CI 1.071\u201342.511];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.009; and HR, 2.078 [95% CI 1.277\u20133.380];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003, respectively), and the involvement of the lacrimal gland (HR, 1.756 [95% CI 1.108\u20132.782];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.017), submandibular gland (HR, 1.654 [95% CI 1.037\u20132.639];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.035), and kidney (HR, 3.413 [95% CI 1.076\u201310.831];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.037) were also risk factors for relapse in group B patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IgG4-RD patients with high serum IgE levels at baseline were more likely to have higher disease activity, and baseline high IgE levels were associated with disease relapse.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-020-02338-1","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T07:02:53Z","timestamp":1603436573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Serum IgE in the clinical features and disease outcomes of IgG4-related disease: a large retrospective cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Jiaxin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1728-2342","authenticated-orcid":false,"given":"Yunyun","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"issue":"6","key":"2338_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMra1104650","volume":"366","author":"JH Stone","year":"2012","unstructured":"Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539\u201351. https:\/\/doi.org\/10.1056\/NEJMra1104650.","journal-title":"N Engl J Med"},{"issue":"9976","key":"2338_CR2","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","volume":"385","author":"T Kamisawa","year":"2015","unstructured":"Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385(9976):1460\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(14)60720-0.","journal-title":"Lancet."},{"key":"2338_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/82_2016_40","volume":"401","author":"M Moriyama","year":"2017","unstructured":"Moriyama M, Nakamura S. Th1\/Th2 immune balance and other T helper subsets in IgG4-related disease. Curr Top Microbiol Immunol. 2017;401:75\u201383. https:\/\/doi.org\/10.1007\/82_2016_40.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"6456","key":"2338_CR4","doi-asserted-by":"publisher","first-page":"eaaw6433","DOI":"10.1126\/science.aaw6433","volume":"365","author":"U Gowthaman","year":"2019","unstructured":"Gowthaman U, Chen JS, Zhang B, Flynn WF, Lu Y, Song W, et al. Identification of a T follicular helper cell subset that drives anaphylactic IgE. Science. 2019;365(6456):eaaw6433. https:\/\/doi.org\/10.1126\/science.aaw6433.","journal-title":"Science"},{"issue":"2","key":"2338_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/all.12320","volume":"69","author":"E Della Torre","year":"2014","unstructured":"Della Torre E, Mattoo H, Mahajan VS, Carruthers M, Pillai S, Stone JH. Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease. Allergy. 2014;69(2):269\u201372. https:\/\/doi.org\/10.1111\/all.12320.","journal-title":"Allergy."},{"key":"2338_CR6","doi-asserted-by":"publisher","unstructured":"Culver EL, Sadler R, Bateman AC, Makuch M, Cargill T, Ferry B, et al. Increases in IgE, eosinophils, and mast cells can be used in diagnosis and to predict relapse of IgG4-related disease. Clin Gastroenterol Hepatol. 2017; 15(9): 1444\u20131452.e6. doi: https:\/\/doi.org\/10.1016\/j.cgh.2017.02.007.","DOI":"10.1016\/j.cgh.2017.02.007"},{"issue":"6","key":"2338_CR7","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/rheumatology\/kev438","volume":"55","author":"ZS Wallace","year":"2016","unstructured":"Wallace ZS, Mattoo H, Mahajan VS, Kulikova M, Lu L, Deshpande V, et al. Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology (Oxford). 2016;55(6):1000\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kev438.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2338_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","volume":"79","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire JF, et al. The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020;79(1):77\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216561.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2338_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.41120","volume":"72","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire JF, et al. The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol. 2020;72(1):7\u201319. https:\/\/doi.org\/10.1002\/art.41120.","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"2338_CR10","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/acr.23543","volume":"70","author":"ZS Wallace","year":"2018","unstructured":"Wallace ZS, Khosroshahi A, Carruthers MD, Perugino CA, Choi H, Campochiaro C, et al. An international multispecialty validation study of the IgG4-related disease responder index. Arthritis Care Res (Hoboken). 2018;70(11):1671\u20138. https:\/\/doi.org\/10.1002\/acr.23543.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"2338_CR11","doi-asserted-by":"publisher","first-page":"10262","DOI":"10.1038\/s41598-018-28405-x","volume":"8","author":"M Shirakashi","year":"2018","unstructured":"Shirakashi M, Yoshifuji H, Kodama Y, Chiba T, Yamamoto M, Takahashi H, et al. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Sci Rep. 2018;8(1):10262. https:\/\/doi.org\/10.1038\/s41598-018-28405-x.","journal-title":"Sci Rep"},{"issue":"1","key":"2338_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13075-018-1567-2","volume":"20","author":"L Wang","year":"2018","unstructured":"Wang L, Zhang P, Wang M, Feng R, Lai Y, Peng L, et al. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients. Arthritis Res Ther. 2018;20(1):65. https:\/\/doi.org\/10.1186\/s13075-018-1567-2.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"2338_CR13","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1002\/art.39205","volume":"67","author":"ZS Wallace","year":"2015","unstructured":"Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kulikova M, Pillai S, Stone JH. IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol. 2015;67(9):2466\u201375. https:\/\/doi.org\/10.1002\/art.39205.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"2338_CR14","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1093\/rheumatology\/kev203","volume":"54","author":"W Lin","year":"2015","unstructured":"Lin W, Lu S, Chen H, Wu Q, Fei Y, Li M, et al. Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients. Rheumatology (Oxford). 2015;54(11):1982\u201390. https:\/\/doi.org\/10.1093\/rheumatology\/kev203.","journal-title":"Rheumatology (Oxford)"},{"key":"2338_CR15","doi-asserted-by":"publisher","unstructured":"Borges T, Silva S. IgG4-related disease: how to place it in the spectrum of immune-mediated and rheumatologic disorders? [published online ahead of print, 2020 Jan 4]. Mod Rheumatol. 2020:1\u20138. https:\/\/doi.org\/10.1080\/14397595.2019.1705537.","DOI":"10.1080\/14397595.2019.1705537"},{"key":"2338_CR16","unstructured":"Fong W, Liew I, Tan D, Lim KH, Low A, Leung YY. IgG4-related disease: features and treatment response in a multi-ethnic cohort in Singapore. Clin Exp Rheumatol. 2018; 36 Suppl 112(3): 89\u201393."},{"issue":"1","key":"2338_CR17","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1038\/s41598-018-23043-9","volume":"8","author":"K Nishida","year":"2018","unstructured":"Nishida K, Gion Y, Takeuchi M, Tanaka T, Kataoka TR, Yoshino T, Sato Y. Mast cells exhibiting strong cytoplasmic staining for IgE and high affinity IgE receptor are increased in IgG4-related disease. Sci Rep. 2018;8(1):4656. https:\/\/doi.org\/10.1038\/s41598-018-23043-9.","journal-title":"Sci Rep"},{"issue":"1","key":"2338_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000023918","volume":"116","author":"D Vercelli","year":"1998","unstructured":"Vercelli D, De Monte L, Monticelli S, Di Bartolo C, Agresti A. To E or not to E? Can an IL-4-induced B cell choose between IgE and IgG4? Int Arch Allergy Immunol. 1998;116(1):1\u20134. https:\/\/doi.org\/10.1159\/000023918.","journal-title":"Int Arch Allergy Immunol"},{"issue":"8","key":"2338_CR19","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1073\/pnas.90.8.3730","volume":"90","author":"J Punnonen","year":"1993","unstructured":"Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G, et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci U S A. 1993;90(8):3730\u20134. https:\/\/doi.org\/10.1073\/pnas.90.8.3730.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2338_CR20","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.cyto.2018.05.009","volume":"110","author":"M Akiyama","year":"2018","unstructured":"Akiyama M, Yasuoka H, Yoshimoto K, Takeuchi T. Interleukin-4 contributes to the shift of balance of IgG subclasses toward IgG4 in IgG4-related disease. Cytokine. 2018;110:416\u20139. https:\/\/doi.org\/10.1016\/j.cyto.2018.05.009.","journal-title":"Cytokine."},{"key":"2338_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2019.02.006","volume":"338","author":"HK Yoon","year":"2019","unstructured":"Yoon HK, Shim YS, Kim PH, Park SR. The TLR7 agonist imiquimod selectively inhibits IL-4-induced IgE production by suppressing IgG1\/IgE class switching and germline \u03b5 transcription through the induction of BCL6 expression in B cells. Cell Immunol. 2019;338:1\u20138. https:\/\/doi.org\/10.1016\/j.cellimm.2019.02.006.","journal-title":"Cell Immunol"},{"issue":"5","key":"2338_CR22","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/14397595.2017.1416891","volume":"28","author":"T Saeki","year":"2018","unstructured":"Saeki T, Kobayashi D, Ito T, Tamura M, Yoshikawa S, Yamazaki H. Comparison of clinical and laboratory features of patients with and without allergic conditions in IgG4-related disease: a single-center experience in Japan. Mod Rheumatol. 2018;28(5):845\u20138. https:\/\/doi.org\/10.1080\/14397595.2017.1416891.","journal-title":"Mod Rheumatol"},{"issue":"7","key":"2338_CR23","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1136\/annrheumdis-2014-205187","volume":"73","author":"E Della-Torre","year":"2014","unstructured":"Della-Torre E, Mattoo H, Mahajan VS, Deshpande V, Krause D, Song P, et al. IgG4-related midline destructive lesion. Ann Rheum Dis. 2014;73(7):1434\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205187.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2338_CR24","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1093\/rheumatology\/keaa221","volume":"59","author":"M Lanzillotta","year":"2020","unstructured":"Lanzillotta M, Campochiaro C, Mancuso G, Ramirez GA, Capurso G, Falconi M, et al. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. Rheumatology (Oxford). 2020;59(9):2435\u201342. https:\/\/doi.org\/10.1093\/rheumatology\/keaa221.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"2338_CR25","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/all.12874","volume":"71","author":"XD Wang","year":"2016","unstructured":"Wang XD, Zheng M, Lou HF, Wang CS, Zhang Y, Bo MY, et al. An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011. Allergy. 2016;71(8):1170\u201380. https:\/\/doi.org\/10.1111\/all.12874.","journal-title":"Allergy."},{"issue":"11","key":"2338_CR26","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3390\/ijerph13111084","volume":"13","author":"QL Fu","year":"2016","unstructured":"Fu QL, Du Y, Xu G, Zhang H, Cheng L, Wang YJ, et al. Prevalence and occupational and environmental risk factors of self-reported asthma: evidence from a cross-sectional survey in seven Chinese cities. Int J Environ Res Public Health. 2016;13(11):1084. https:\/\/doi.org\/10.3390\/ijerph13111084.","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"2338_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/all.12342","volume":"69","author":"H Mattoo","year":"2014","unstructured":"Mattoo H, Della-Torre E, Mahajan VS, Stone JH, Pillai S. Circulating Th2 memory cells in IgG4-related disease are restricted to a defined subset of subjects with atopy. Allergy. 2014;69(3):399\u2013402. https:\/\/doi.org\/10.1111\/all.12342.","journal-title":"Allergy."},{"issue":"6","key":"2338_CR28","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.anai.2020.03.024","volume":"124","author":"E Della-Torre","year":"2020","unstructured":"Della-Torre E, German\u00f2 T, Ramirez GA, Dagna L, Yacoub MR. IgG4-related disease and allergen-specific immunotherapy. Ann Allergy Asthma Immunol. 2020;124(6):631\u20133. https:\/\/doi.org\/10.1016\/j.anai.2020.03.024.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"2338_CR29","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/joim.12942","volume":"286","author":"Y Peng","year":"2019","unstructured":"Peng Y, Li JQ, Zhang PP, Zhang X, Peng LY, Chen H, et al. Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study. J Intern Med. 2019;286(5):542\u201352. https:\/\/doi.org\/10.1111\/joim.12942.","journal-title":"J Intern Med"},{"issue":"1","key":"2338_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/MD.0b013e3182431ef6","volume":"91","author":"A Khosroshahi","year":"2012","unstructured":"Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore). 2012;91(1):57\u201366. https:\/\/doi.org\/10.1097\/MD.0b013e3182431ef6.","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"2338_CR31","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1093\/rheumatology\/kez669","volume":"59","author":"Y Liu","year":"2020","unstructured":"Liu Y, Zeng Q, Zhu L, Gao J, Wang Z, Wang Z, et al. Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort. Rheumatology (Oxford). 2020;59(8):2115\u201323. https:\/\/doi.org\/10.1093\/rheumatology\/kez669.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"2338_CR32","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2018-214603","volume":"78","author":"ZS Wallace","year":"2019","unstructured":"Wallace ZS, Zhang Y, Perugino CA, Naden R, Choi HK, Stone JH, et al. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis. 2019;78(3):406\u201312. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214603.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02338-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02338-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02338-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T20:03:39Z","timestamp":1634933019000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02338-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2338"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02338-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-47607\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-47607\/v2","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]},"assertion":[{"value":"26 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study complied with the Declaration of Helsinki and was reviewed and approved by the Ethics Committee of Peking Union Medical College Hospital. All recruited patients signed informed consent forms.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We obtained consent for publication from all the individuals whose detailed information was included in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"255"}}